SMSarah Allison Milgrom

Sarah Allison Milgrom

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sarah Allison Milgrom has a total of 323 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Incorporating Intensity Modulated Total Body Irradiation (IMRT-TBI) Into Future Cooperative Group Clinical Trials: An NRG Hematologic Malignancies Working Group-Led Report From the National Clinical Trials Network

    by Nataliya Kovalchuk, Eric A. Simiele, Michael LaRiviere, Susan M. Hiniker, Michael Soike, Chunhui Han, Jeffrey Wong, Savita Dandapani, Kiran Kumar, David Parsons, et al.


  • Subsequent Neoplasm Risk After Modern Mediastinal Radiation Therapy for Pediatric Hodgkin Lymphoma: Insights From a Multi-Institutional Children’s Oncology Group Trial

    by Sarah A. Milgrom, Harald Paganetti, Hitesh Dama, Lindsay Renfro, Yue Wu, Isaac Meyer, Meenakshi Jeeva, Susan K. Parsons, Angela Punnett, Anne-Marie Charpentier, et al.


  • Imaging pitfalls in pediatric, adolescent, and young adult Hodgkin lymphoma: a SEARCH for CAYAHL initiative to bridge multidisciplinary patient care

    by Nawar Dakhallah, Jonas Steglich, Claire Gowdy, Sarah A Milgrom, Adina L Alazraki, Sharon M Castellino, Karin Dieckmann, Jamie E Flerlage, Mallorie B Heneghan, Kara M Kelly, et al.

    Pediatric Hodgkin lymphoma (pHL) is a highly curable malignancy in children, adolescents, and young adults, and current treatment strategies aim to minimize adverse late effects. Many patients are enrolled in clinical trials with centralized review for both initial and interim staging. Although academic guidelines provide a structured framework for image interpretation, real-world clinical scenarios sometimes present imaging pitfalls that require nuanced judgment. Morphological and metabolic imaging pitfalls refer to misinterpretation of findings that occur during staging, disease evaluation, or post-treatment surveillance. In pHL, such pitfalls may result from suboptimal imaging conditions, concurrent inflammatory, infectious, or other findings. These findings do not indicate neoplastic disease but rather are manifestations of other processes specific to each tissue or organ. This Staging, Evaluation, and Response Criteria Harmonization for Childhood, Adolescent, and Young Adult Hodgkin Lymphoma (SEARCH for CAYAHL) initiative represents a transatlantic collaboration among multidisciplinary professionals, aiming to disseminate the insights gained from decades of centralized review experience in North American and European clinical trials. This article aims to optimize patient care by integrating imaging and clinical expertise in disease staging and surveillance. Although not intended as a comprehensive staging guide, it highlights recurrent imaging pitfalls that may lead to incorrect staging or response assessment. By encouraging interdisciplinary exchange, this work seeks to complement existing literature and serve as a troubleshooting guide for situations where clinical realities diverge from academic paradigms.

  • Shifting the Balance of Therapeutic Radiation in Adolescent and Young Adult Hodgkin Lymphoma

    by Sarah A. Milgrom, Sharon M. Castellino

    Over recent decades, the use of radiotherapy (RT) in classic Hodgkin lymphoma has shifted toward more conservative, individualized application. In this issue of Cancer Epidemiology, Biomarkers & Prevention, Corrigan and colleagues report on real-world RT utilization trends in adolescent and young adult (AYA) patients in the National Cancer Database who were treated for classic Hodgkin lymphoma from 2004 to 2020 in the United States. The findings parallel broader trends seen in pediatric and adult classic Hodgkin lymphoma toward a lower proportion of patients receiving RT and a reduction in the anatomic regions targeted with RT. Additionally, Corrigan and colleagues identified several demographic factors that were associated with RT receipt, at least some of which may reflect systemic disparities in healthcare delivery. As management strategies in AYA classic Hodgkin lymphoma continue to evolve, ongoing study using large databases will be critical to assess the adoption of evidence-based, equitable practices that maximize disease control and minimize deleterious late effects. The AYA population warrants special attention given their unique characteristics that may affect treatment strategies and patterns of care. See related article by Corrigan et al., p. 1483


  • Effect of Pelvic External Beam Radiation Therapy on Lower Urinary Tract Function of Pediatric Patients

    by Michael H. Edwards, Andrew Nicklawsky, Gemma Beltran, Elizabeth Stein, Jennifer Pyrzanowski, Kyle Rove, Karlie Boone, Sarah Milgrom, Nicholas G. Cost

    Background: Pediatric patients with pelvic solid tumors often receive multimodal treatment, but the long‐term effects of this treatment on lower urinary tract (LUT) function are not well‐described. This prospective cohort study (NCT05818462) investigates the effect of external beam radiation therapy (EBRT) on LUT function by comparing patient‐reported outcome measures, non‐invasive urodynamic studies, and post‐void residuals (PVRs) amongst childhood cancer survivors (CCS).Methods: All subjects were CCS greater than 1 year off‐therapy for a pediatric solid tumor. Subjects were divided into cohorts by whether they had received pelvic EBRT. Research subjects completed the Dysfunctional Voiding Scoring system (DVSS) survey, uroflow testing, and PVR bladder scan.Results: Thirty‐two patients enrolled; half received pelvic EBRT (mean 30.0 Gy). There was an equal number of patients exposed to alkylators (69%) in each cohort. Radiation cohort was further off therapy (5.3 vs. 4.0 years). The pelvic radiation cohort was more likely to have abnormal uroflow patterns (81% vs. 56%, p = 0.12). The flow pattern distribution differed between groups (p = 0.03); the pelvic radiation cohort was more likely to have a “plateau”‐shaped curve (44% vs. 6%) and abnormal PVR (odds ratio [OR] 9.0, p = 0.002). Exploratory conditional likelihood ratio models yielded potential associations between pelvic EBRT and LUTD, as well as a potential dose–response. There was no difference in DVSS scores between cohorts.Conclusion: EBRT appears to affect LUT function in CCS who received pelvic EBRT. DVSS does not appear useful as a screening tool in this population. Further study is needed to better appreciate the impact of EBRT on LUT function and develop more accurate screening tools.


  • Open Access

    Effect of Pelvic Beam Radiation Therapy on Lower Urinary Tract Function of Pediatric Patients

    by Michael H. Edwards, Andrew Nicklawksi, Gemma Beltran, Elizabeth Stein, Jennifer Pyrzanowski, Kyle O. Rove, Karlie Boone, Sarah Milgrom, Nicholas Cost

    Background : Pediatric patients with pelvic solid tumors often receive multi-modal treatment but the long-term effects of this treatment on lower urinary tract (LUT) function are not well-described. This prospective cohort study (NCT05818462) investigates the effect of EBRT on LUT function by comparing patient-reported outcome measures, non-invasive urodynamic studies, and post-void residuals (PVRs) amongst childhood cancer survivors (CCS). Methods : All subjects were CCS >1 year off-therapy for a pediatric solid tumor. Subjects were divided into two cohorts: a study cohort of patients who received pelvic EBRT and a control cohort who received only chemotherapy. Research subjects completed the Dysfunctional Voiding Scoring system (DVSS) survey, uroflow testing, and PVR bladder scan. Results : Thirty-two patients enrolled. Sixteen patients received pelvic EBRT. There were an equal number of patients exposed to alkylators (69%) in each cohort. The study cohort was more likely to have abnormal uroflow patterns (81% vs 56%, p=0.12). The flow pattern distribution differed between groups (p=0.03); the study cohort was more likely to have a “plateau” shaped curve (44% vs 6%) and abnormal PVR (OR 9.0, p=0.002). Exploratory conditional likelihood ratio models yielded potential associations between pelvic EBRT and LUTD, as well as a potential dose-response. There was no difference in DVSS scores between cohorts. Conclusion : EBRT appears to affect LUT function in CCS who received pelvic EBRT. DVSS does not appear useful as a screening tool in this population. Further study is needed to better appreciate the impact of EBRT on LUT function and develop more accurate screening tools.

  • Curative Treatment of Pediatric Hodgkin Lymphoma With Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine and Consolidation Radiotherapy: A Systematic Review and Suggested Recommendations

    by Josué Hernández-Benítez, Alejandra López-Azcarraga, Jamie E. Flerlage, Sharon Castellino, Paula Aristizabal, Bradford S. Hoppe, Sarah A. Milgrom, Mario José Aguiar de Paula, Raymond B. Mailhot Vega

    PURPOSE: Doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) chemotherapy is used commonly for pediatric Hodgkin lymphoma (pHL) in low- and middle-income countries. The role of radiotherapy (RT) after ABVD in pHL is uncertain. MATERIALS AND METHODS: We conducted a systematic review to explore the use of ABVD with or without RT in pHL. Key clinical questions included the number of cycles of ABVD, indications for and dose of RT, and outcomes by risk group. A search was performed in PubMed. Articles reporting survival outcomes by risk group were included. RESULTS: Of 97 articles identified in the literature search, nine met inclusion criteria. Chemotherapy consisted of four to six cycles in limited disease and mostly six cycles in advanced disease. Three studies used RT for all patients within a specified risk group. Six studies dictated an adapted RT approach, with 3%-43% of the patients receiving RT for bulky adenopathy, slow early response (SER), and/or incomplete response. Radiation doses ranged between 20 and 36 Gy. The progression-free survival and overall survival at 4-10 years ranged from 84% to 100% and 93%-100% in limited disease and 50%-84.4% and 75%-95.3% in advanced disease, respectively. Studies did not directly assess the impact of certain chemotherapy or RT strategies. Recommendations were made after reviewing outcomes with particular approaches. CONCLUSION: Four cycles of ABVD are recommended for limited disease, and six cycles of ABVD are recommended for advanced disease. In both limited and advanced diseases, RT is recommended with a dose of 20-21 Gy only to sites of bulky and/or SER, with a boost of up to 36 Gy to sites of incomplete response. This approach could spare radiation for at least half of the patients with limited disease and one third of advanced disease.

  • Does pre-irradiation gross tumor volume predict the risk of progression after radiation therapy in pediatric patients with adamantinomatous craniopharyngioma?

    by Tamar Brooks, Dexiang Gao, Kathleen Dorris, Karlie Boone, David M. Mirsky, Susan Staulcup, Eric Prince, Marina Moskalenko, Elizabeth Ignowski, Narine Wandrey, et al.

    OBJECTIVE: In a cohort of patients who were treated with resection and adjuvant radiotherapy (RT) for adamantinomatous craniopharyngioma (ACP), the authors aimed to determine whether gross tumor volume (GTV) at the initiation of RT was associated with the risk of progressive disease (PD) following treatment. METHODS: Pediatric and adolescent patients who received surgery and RT for ACP at a single institution from 1998 to 2021 were identified. Univariable Cox regression analyses (UVAs) were performed to assess the association between pre-RT GTV and PD after RT. Multivariable analyses (MVAs) were used to control for potential confounders. Two different endpoints were used to define PD. The first definition was based on radiographic tumor growth, with or without progression of clinical symptoms. The second definition was the requirement for an additional tumor-directed intervention following the completion of RT. RESULTS: Forty-eight patients were eligible for inclusion. The median age at diagnosis was 7.9 years (range 2.1–17.4 years). All patients were treated with surgery and RT with a median dose of 52.2 Gy (range 45–55.8 Gy) and median GTV of 9.86 cm3 (range 0.7–117.7 cm3). After a median follow-up of 66.4 months, 8 patients experienced PD based on both definitions. The 5-year event-free survival rate was 85.4% (95% CI 74.1%–98.3%). On both UVA and MVA, GTV was significantly associated with an increased likelihood of PD (UVA: HR 1.02, 95% CI 1.00–1.04, p = 0.02; MVA: HR 1.10, 95% CI 1.02–1.19, p = 0.01). However, after exclusion of a single outlier with a GTV of 117.7 cm3 prior to RT (remainder of the cohort: range 0.7–37.3 cm3), a second analysis identified no significant association between GTV and PD (UVA: HR 1.03, 95% CI 0.96–1.10, p = 0.4; MVA: HR 1.06, 95% CI 0.96–1.17, p = 0.24). CONCLUSIONS: The authors conclude that for most children and adolescents with ACP, the GTV at the initiation of RT is not associated with the risk of PD. This finding may influence surgical practice, because it suggests that aggressive tumor debulking for the purpose of improving the efficacy of RT may not be necessary. In the case of giant tumors, however, novel strategies may be needed for tumor control.


  • Primary Central Nervous System Lymphoma

    by Brandon S. Imber, Kathryn R. Tringale, Sarah A. Milgrom, Joachim Yahalom